Objective: Emerging evidence suggests associations between menopausal hot flashes and cardiovascular risk. However, whether hot flashes are associated with intima media thickness (IMT) or IMT changes over time is unknown. We hypothesized that reported hot flashes would be associated with greater IMT cross-sectionally and with greater IMT progression over 2 years.
M ore than 70% of women report hot flashes during the menopausal transition. 1 Hot flashes are associated with impairments in quality of life, 2 particularly sleep disruption, 3 depressed mood, 4 and possibly memory problems. 5 Most women with menopausal symptoms, principally hot flashes, seek treatment for them. 6 In addition to their quality-of-life implications, emerging research suggests associations between hot flashes and cardiovascular risk. In the Women's Health Initiative, the greatest cardiovascular risk associated with hormone therapy (HT) use was among the older postmenopausal women reporting moderate-severe hot flashes at baseline. 7 A similar pattern of findings was observed in the Heart and Estrogen/Progestin Replacement Study, a study of older postmenopausal women with heart disease. 8 We found among midlife women participating in the Study of Women's Health Across the Nation (SWAN) Heart that hot flashes were associated with poorer flow-mediated dilation and higher aortic calcification, 9 two subclinical CVD measures. These associations persisted after controlling for CVD risk factors and estradiol (E 2 ) concentrations.
However, contradictory findings exist. In one study, pulse wave velocity was inversely related to subjective hot flash severity ratings, 10 but markers of atherosclerosis were not included. In another study, endothelial function, but not carotid intima media thickness (IMT), differed between women with no to mild hot flashes and women with moderate to severe hot flashes. 11 Given these suggestive yet not entirely consistent findings, there have been calls for increased research on links between hot flashes and CVD risk. 12 In our present work, we examined the relations between hot flashes and carotid IMT. IMT as measured by B-mode ultrasound is one of the most widely used and well-validated measures of subclinical CVD. 13 We hypothesized that hot flashes will be cross-sectionally associated with higher IMT, controlling for CVD risk factors and E 2 concentrations, two key mechanisms that may link hot flashes to IMT. 1,14<16 We also hypothesized that hot flashes will be associated with greater progression in IMT over two time points. Finally, we examined interactions between hot flashes and HT use, age, menopausal stage, and body mass index (BMI) in relation to IMT, as these factors can play key roles in relations between hot flashes and CVD risk. 7<9 
METHODS

Study population
SWAN is a cohort study designed to characterize the menopausal transition, conducted at seven sites across the United States. Details of the study design and procedures have been reported previously. 17 At enrollment (1996) (1997) , SWAN participants (n = 3,302) were aged 42 to 52 years, had an intact uterus and one or more ovary, were not pregnant or breastfeeding, had menstruated within 3 months, and were not using oral contraceptives or HT. The study was approved by the institutional review board at each site. Each participant provided written informed consent.
A subcohort of participants at the Pittsburgh and Chicago SWAN sites participated in SWAN Heart, an ancillary study carried out to assess cardiovascular risk during the menopausal transition. SWAN Heart included two assessments, the baseline examination, occurring once during SWAN study years 4 to 7 (2001-2005) , and the follow-up examination, occurring 2 years later during SWAN study years 6 to 9 (2003-2008) . Each SWAN Heart visit occurred within 3 months of the corresponding annual core SWAN assessment. By design, 17 the Pittsburgh and Chicago sites recruited only non-Hispanic white and black women. Therefore, SWAN Heart participants described themselves as white or black. Eligible SWAN participants were invited to participate in SWAN Heart; of these women, 76% enrolled. SWAN Heart exclusion criteria were pregnancy, hysterectomy or bilateral oophorectomy, reported CVD (prior myocardial infarction, angina, stroke, transient ischemia, peripheral vascular disease, other vascular disease including fibromuscular dysplasia, or collagen vascular disease), diabetes, or medications to treat these conditions. Women who used HT (ie, estrogen with or without progesterone and hormonal contraceptives) were also excluded, with one caveat. Women at the Pittsburgh site had been recruited for a subclinical CVD study at core SWAN visits 0 and 1 with similar study criteria. When SWAN Heart began during visits 4 to 7, the decision was made to enroll them in SWAN Heart even if they did not meet certain study criteria. Thus, by the time these women underwent subclinical CVD assessments in SWAN Heart, 53 women were using HT. HT use was considered as a covariate in all analyses.
Of the 588 SWAN Heart participants, 493 and 433 women provided information on hot flashes and underwent carotid ultrasounds at baseline and follow-up, respectively. There were 61 and 67 women excluded from the baseline and follow-up models, respectively, because of missing values on covariates or oophorectomy by the follow-up. Excluded women were more likely to be black, to be smokers, and to have a higher BMI, higher systolic (SBP) and diastolic (DBP) blood pressure, higher glucose level, higher follow-up IMT, and lower physical activity (all p G 0.05) than were included women. Missing BMI, blood pressure, lipid, glucose, and smoking values were carried forward from the last completed assessment. Thus, the samples used to evaluate primary hypotheses consisted of 432 women at baseline, 366 at follow-up, and 346 in models over the two visits.
Design and procedures
Participants completed a standard protocol at SWAN entry and annually thereafter, including questionnaires, blood specimens, anthropometric measures, and blood pressure readings. Carotid ultrasonography was initiated during the SWAN Heart baseline visit and repeated at the SWAN Heart follow-up visit 2 years later.
Intima media thickness
IMT was assessed by B-mode ultrasonography of the left and right carotid arteries with a Hewlett-Packard 5500 scanner (Hewlett-Packard, Andover, MA) at the Chicago site and a Toshiba SSA-270A scanner (Toshiba American Medical Systems, Tustin, CA.) at the Pittsburgh site. Image quality was comparable between the two systems. Images were obtained from four locations of the left and right carotid arteries: the near and far walls of the distal common carotid artery, the far wall of the bulb, and the first centimeter of the far wall of the internal carotid artery. IMT measures were performed by electronically tracing the lumen-intima interface and the media-adventitia interface across 1-cm segments in these locations. One measure is generated for each pixel, for a total of È140 measures per segment. The mean of average readings across the eight locations comprised the average IMT. Readings were conducted at the University of Pittsburgh Ultrasound Research Laboratory under the direction of Dr. Sutton-Tyrrell. Readers were recertified annually against the same set of scans to guard against reader drift. Replicate IMT readings were performed on 20 scans (intraclass correlation, 0.98). Previous reports using the same laboratory and duplex scanning protocol have also shown high reproducibility. 18 
Hot flashes
At the annual SWAN interviews corresponding to the SWAN Heart baseline and follow-up visits, participants reported the number of days in which hot flashes were experienced in the 2 weeks before the interview (not at all, 1-5 d, 6-8 d, 9-13 d, every day). Women were categorized as experiencing hot flashes on no days, 1 to 5 days, or 6 days or more in the past 2 weeks. To examine the stability of hot flashes across visits, women were also categorized as experiencing hot flashes at neither, one, or both visits. Night sweats were examined and showed similar yet attenuated patterns of associations in relation to IMT, but findings were largely nonsignificant and are thus not reported here.
Estradiol
Measures were obtained from a morning fasting blood sample during the annual SWAN visit corresponding to SWAN Heart baseline. Participants were scheduled for venipuncture on days 2 to 5 of a spontaneous menstrual cycle. Two attempts were made for a timed sample, obtained for 35% of participants. If a timed sample could not be obtained, a random fasting sample was taken. Blood was refrigerated before centrifugation 1 to 2 hours after phlebotomy, and serum was aliquotted, frozen, and batched for shipment to the central laboratory. Samples were catalogued upon arrival, and batches were assayed monthly. Assays were performed on the ACS-180 automated analyzer (Bayer Diagnostics, Tarrytown, NY) using a doubleantibody chemiluminescent immunoassay with a solid-phase antiYimmunoglobulin G (IgG) conjugated to paramagnetic particles, antiligand antibody, and competitive ligand labeled with dimethylacridinium ester. The assay modified the rabbit anti-E2-6 ACS-180 immunoassay to increase sensitivity (lower limit of detection, 1.0 pg/mL). Duplicate assays were conducted, with results reported as the arithmetic mean for each participant, with a coefficient of variation of 3% to 12%.
Covariates
Race/ethnicity, education (ehigh school, some college/ vocational, or Qcollege degree), and lipid levels were derived from the baseline SWAN interview and SWAN Heart examination. All other covariates were derived from the annual SWAN interview/examination corresponding to the SWAN Heart visit. Age was considered as a continuous variable. Race/ethnicity was determined in response to BHow would you describe your primary racial or ethnic group?[ Menopause status, obtained annually from reported bleeding patterns, was categorized as premenopausal (bleeding in the previous 3 mo with no change in cycle predictability in the past year), early perimenopausal (bleeding in the previous 3 mo with a decrease in cycle predictability in the past year), late perimenopausal (93-G12 mo amenorrhea), or postmenopausal (Q12 mo amenorrhea). Because of small cell sizes, premenopausal and early perimenopausal women were combined for analysis. Women last classified as premenopausal or perimenopausal who reported taking hormones (oral contraceptives, oral estrogens and/or progestins, estrogen injections, or patch) in the past year were considered indeterminate status because of the impact of hormone use, even if discontinued, on bleeding patterns. Women taking hormones within the past month, regardless of the last known menopause status, were classified as HT users. Physical activity was assessed via a modified Kaiser Permanente Health Plan Activity Survey. 19 CVD conditions (reported hypertension and, relevant to the follow-up visit, angina, stroke, and myocardial infarction) and CVD medications (reported use of medication for a heart condition or for blood pressure lowering in the past year) were combined into a single variable. Diabetes history/medication use, relevant to the follow-up visit, was the report of having diabetes/current use of medications for treatment of diabetes. Anthropometric measures (height, weight, SBP, and DBP), as well as total serum cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglyceride, and glucose levels from a fasting blood sample, were obtained using standard methods. BMI was calculated as weight (kg)/height (m) 2 and considered as a continuous covariate.
Statistical analysis
Variables were examined for distributions, outliers, and small cell sizes. HDL, triglycerides, glucose (baseline only), and E 2 were log transformed before analysis because of evidence of skewness. Univariate associations between hot flashes and covariates were evaluated via analysis of variance, linear regression, and logistic regression. Multiple linear regression was used to evaluate cross-sectional associations between hot flashes and IMT at baseline and follow-up, as well as relations between hot flashes across visits and follow-up IMT or IMT progression. IMT progression was calculated as follow-up IMT j baseline IMT. IMT progression was alternatively evaluated by examining the associations between hot flashes and follow-up IMT controlling for baseline IMT. Because there were no significant associations between hot flashes and IMT progression with either approach, nor when stratified by obesity status, data for progression models are not presented. Covariates were site, race, education, menopause status, BMI, smoking status, diabetes status/medication use, CVD status/medication use, HT, SBP, DBP, HDL, LDL, triglycerides, glucose, and physical activity. For hormonal models, E 2 was added to risk factorYadjusted models, with timing (cycle day) of blood draw also covaried. Because of collinearity between blood draw timing and menopause status, only blood draw timing was included in the statistical models. Interactions by age, race, HT, BMI, and menopausal stage were evaluated in primary models via cross-product interaction terms between hot flashes and each potential effect modifier. Analyses were performed with SAS (v.9.2, SAS Institute, Cary, NC). All tests were two sided (> = 0.05).
RESULTS
At the SWAN Heart baseline, women with hot flashes were older, less often white, had a lower education, were later in the menopausal transition, and had higher BMI, higher SBP, higher glucose level, higher LDL level, and lower E 2 level than did women without hot flashes (Table 1) . Forty-six percent of the women reported hot flashes at baseline and 54% of the women reported hot flashes at the follow-up. When considering the trajectory of hot flashes across visits, 37.9% (n = 131) of women had no hot flashes, 28.9% (n = 100) had hot flashes at one visit, and 33.2% (n = 115) had hot flashes at both visits. Mean (SD) IMT was 0.67 (0.086) mm at the SWAN Heart baseline and 0.71 (0.093) mm at the follow-up. Mean (SD) IMT progression across visits was 0.037 (0.064) mm.
At baseline, having hot flashes for 6 days or more in the past 2 weeks was associated with higher IMT in the risk factorYadjusted models; further adjustment for E 2 somewhat attenuated these associations ( Table 2) . At the follow-up visit, reporting hot flashes for 6 days or more in the past 2 weeks was associated with higher IMT in the risk factorYadjusted models; these associations remained significant with adjustment for E 2 (Table 3 ). Furthermore, hot flashes at both visits were associated with higher follow-up IMT in both the risk factorY and E 2 -adjusted models. In contrast to the risk factorY adjusted models, in the minimally adjusted (age, site, and race) models, associations between hot flashes and IMT showed a similar, but less pronounced, pattern of associations at baseline No interactions between age, race, HT use, or menopause status and hot flashes in relation to IMT were observed. There was an indication of an interaction between hot flashes and BMI in relation to baseline (P = 0.05) and follow-up IMT (P = 0.05) and, to a lesser extent, for hot flashes across visits and follow-up IMT (P = 0.10). Relations between hot flashes and IMT were most pronounced among overweight/obese women (Fig. 1) .
Findings for night sweats showed a similar yet attenuated pattern to those for hot flashes in the risk factorYadjusted models at baseline (night sweats, none vs Q6 nights in the 
DISCUSSION
This study suggests that women reporting hot flashes for 6 days or more in the prior 2 weeks may have higher IMT than do women reporting no hot flashes. Although findings were not entirely consistent, greater hot flash reporting was generally associated with higher IMT, with associations apparent after controlling for traditional CVD risk factors. E 2 accounted for a portion, but not all, of the associations between hot flashes and IMT. Although the magnitude of the association between hot flashes and IMT was modest, it was consistent with effect sizes observed for obesity, smoking, and menopause status in relation to IMT in this sample. Moreover, associations were principally observed among overweight and obese women. Hot flashes were not associated with IMT progression.
IMT is one of the most widely used and well-validated measures of subclinical CVD. Higher IMT has been associated with increased CVD risk factors, atherosclerosis, prev-alent CVD, and prospectively with incident CVD events. 13, 20 The predictive value of IMT is particularly evident among low-risk individuals, 21 such as the women in this study. Thus, when these results are considered in conjunction with our prior work with this cohort, 9 we see that SWAN Heart participants reporting hot flashes, particularly every other day or more, had increased subclinical CVD, including higher IMT, aortic calcification, and poorer flow-mediated dilation, than do women without hot flashes.
Our findings are largely consistent with prior work from clinical trials 7, 8 and observational epidemiologic studies 9, 22 showing associations between hot flashes and cardiovascular risk. However, there are inconsistencies in this literature. In one study, pulse wave velocity was inversely related to subjective hot flash severity ratings, 10 although in that study, there were few women without hot flashes and markers of atherosclerosis were not included. In another study, having both hot flashes and night sweats was associated with reduced mortality risk, but relations were null when adjusting for confounders. 23 Finally, another study found that women with moderate to severe hot flashes had poorer endothelial function, but not IMT, than did women with no/mild hot flashes. 11 Notably, their ability to detect associations for IMT, versus endothelial dysfunction typically evident earlier in the disease process, was limited by their exceptionally healthy sample and very low IMT levels.
Associations between hot flashes and IMT in this study were observed primarily among overweight and obese women. Notably, the overweight/obese women in this sample had higher mean IMT and variability in IMT than did lean women, increasing the likelihood of detecting associations. Furthermore, overweight and obese women have more hot flashes relative to lean women. 1 Finally, this work may suggest a synergistic effect between hot flashes and existing CVD risk factors with respect to IMT, which should be considered in future work. Consistent with our prior research among midlife women, 9 no interactions were observed between hot flashes and age, menopausal stage, or HT use, indicating that findings extend across these groups.
The mechanisms underlying links between hot flashes and cardiovascular risk require greater elucidation. Current models characterize hot flashes as thermoregulatory events occurring in the context of menopausal endocrine changes. 24 However, the physiology of hot flashes is not well understood, and many other systems have been implicated. The low E 2 that may play a role in the etiology of hot flashes is generally associated with a poorer cardiovascular profile. 15, 16 However, adjustment for endogenous E 2 attenuated, but did not fully eliminate, the associations between hot flashes and IMT. Furthermore, CVD risk factors such as smoking and obesity are risk factors for hot flashes, 1, 14 and some studies have shown adverse metabolic 1 or blood pressure 14 profiles with hot flashes. Residual confounding is always possible in observation research, although it is notable that relations between hot flashes and IMT were not reduced but in fact strengthened after controlling for CVD risk factors. The reason for this pattern of associations is not entirely clear but does not support the notion that the CVD risk factors accounted for these relations. Finally, our prior research showed acute decreases in cardiac vagal control during hot flashes, 25 and our prior work 9 and that of others 11 suggested poorer endothelial function associated with hot flashes. These systems may be relevant to understanding the associations observed here. Given evidence of links between hot flashes and cardiovascular risk, further investigation of potential underlying mechanisms is needed.
A unique aspect of this study is its consideration of the relations between hot flashes and IMT in the longitudinal setting. We observed cross-sectional relations between hot flashes and IMT, as well as reporting hot flashes at both visits being associated with higher IMT. However, hot flashes were not associated with IMT progression. IMT was assessed 2 years apart, and although statistically significant progression was observed, the magnitude of this change was small. Calculation of IMT progression includes error from both baseline and follow-up measurements, limiting the ability to detect differences in progression by hot flash status. Furthermore, the reduction in E 2 that accompanies menopause can be associated with vascular adaptation 16 that would affect IMT and make detection of clear changes between these two time points challenging. 26 Thus, these results support a link between hot flashes and subclinical CVD but not a role for hot flashes in the progression of IMT, although further research on progression over longer follow-up times and into older ages is warranted.
Several limitations deserve mention. Hot flashes were characterized using a brief, self-report measure. Although common in epidemiologic investigations, these measures provide limited information about hot flashes and are subject to memory biases. Future work should use more detailed hot flash measures. Moreover, E 2 was characterized via a single annual blood sample, which may not have fully characterized E 2 exposure, particularly among perimenopausal women experiencing wide hormonal fluctuations. Although daily assessments were not feasible in this epidemiologic study, more detailed assessments should be undertaken in future work. Furthermore, excluded women had a higher risk profile with respect to CVD and possibly hot flashes than did included women; therefore, associations may have been underestimated here. Finally, power may have been insufficient to fully assess interactions by relevant subject characteristics; these subanalyses should be undertaken in future work with larger sample sizes and across a range of menopausal stages not fully represented here (ie, premenopausal women and late postmenopausal women).
The present investigation has several strengths. It is the first to examine the relations between hot flashes and IMT in a community-dwelling sample of midlife women, demonstrating significant associations with this widely validated subclinical CVD measure. The study included sizeable numbers of black and white women, indicating that associations extend to both groups. It allowed consideration of associations longitudinally, showing the pattern and consistency of associations between hot flashes and IMT over time. Finally, the study included a sample of well-characterized women that was followed throughout the menopausal transition.
CONCLUSIONS
The present work adds to the growing body of literature concerning hot flashes and CVD. Notably, hot flashes occur at a time of life characterized by increasing CVD risk for women. The precise nature of relations between hot flashes and cardiovascular risk requires greater explication. With additional research, investigators will be able to more conclusively determine whether hot flashes mark adverse underlying vascular changes, potentially signaling to clinicians the need for more aggressive traditional CVD risk factor reduction among women with hot flashes. These findings also may have implications for understanding the physiology of hot flashes, suggesting consideration of vascular involvement in hot flashes. This work supports the importance of continued work to further understand the role of hot flashes in cardiovascular risk.
